UB Paderborn / Katalog / Suche / in CDI

Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers

Clinical cancer research, 2019-08, Vol.25 (15), p.4723-4734

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of a HER2-Targeted Thorium-227 Conjugate in a HER2-Positive Breast Cancer Bone Metastasis Model

Cancers, 2023-06, Vol.15 (13), p.3419

2023

Link zum Volltext

Verfügbarkeit prüfen

Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer

Clinical cancer research, 2020-04, Vol.26 (8), p.1985-1996

2020

Link zum Volltext

Verfügbarkeit prüfen

In Vitro and In Vivo Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia

Molecular cancer therapeutics, 2016-10, Vol.15 (10), p.2422-2431

2016

Link zum Volltext

Verfügbarkeit prüfen

Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy

Cancer biotherapy & radiopharmaceuticals, 2020-09, Vol.35 (7), p.497

2020

Link zum Volltext

Verfügbarkeit prüfen

Solution Thermodynamics and Kinetics of Metal Complexation with a Hydroxypyridinone Chelator Designed for Thorium-227 Targeted Alpha Therapy

Inorganic chemistry, 2018-11, Vol.57 (22), p.14337-14346

2018

Link zum Volltext

Verfügbarkeit prüfen

A Combined Experimental and Density Functional Theory Investigation of Hydrocarbon Activation at a Cationic Platinum(II) Diimine Aqua Complex under Mild Conditions in a Hydroxylic Solvent

Journal of the American Chemical Society, 2000-11, Vol.122 (44), p.10831-10845

2000

Link zum Volltext

Verfügbarkeit prüfen

An efficient chelator for complexation of thorium-227

Bioorganic & medicinal chemistry letters, 2016-09, Vol.26 (17), p.4318-4321

2016

Link zum Volltext

Verfügbarkeit prüfen

Preclinical Combination Studies of an FGFR2 Targeted Thorium-227 Conjugate and the ATR Inhibitor BAY 1895344

International journal of radiation oncology, biology, physics, 2019-10, Vol.105 (2), p.410-422

2019

Link zum Volltext

Verfügbarkeit prüfen

Development of separation technology for the removal of radium-223 from targeted thorium conjugate formulations. Part II: purification of targeted thorium conjugates on cation exchange columns

Drug development and industrial pharmacy, 2017-09, Vol.43 (9), p.1440-1449

2017

Link zum Volltext

Verfügbarkeit prüfen

Development of separation technology for the removal of radium-223 from targeted thorium conjugate formulations. Part I: purification of decayed thorium-227 on cation exchange columns

Drug development and industrial pharmacy, 2017-02, Vol.43 (2), p.225-233

2017

Link zum Volltext

Verfügbarkeit prüfen

Development of separation technology for the removal of radium-223 from decayed thorium-227 in drug formulations. Material screening and method development

Drug development and industrial pharmacy, 2016-08, Vol.42 (8), p.1215-1224

2016

Link zum Volltext

Verfügbarkeit prüfen

Synergistic Effect of a Mesothelin-Targeted 227Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models

The Journal of nuclear medicine (1978), 2019-09, Vol.60 (9), p.1293-1300

2019

Link zum Volltext

Verfügbarkeit prüfen

Synergistic Effect of a Mesothelin-Targeted 227 Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models

Journal of Nuclear Medicine, 2019-09, Vol.60 (9), p.1293-1300

2019

Link zum Volltext

Verfügbarkeit prüfen

Hydrocarbon Activation at a Cationic Platinum(II) Diimine Aqua Complex under Mild Conditions in a Hydroxylic Solvent

Journal of the American Chemical Society, 1999-03, Vol.121 (9), p.1974-1975

1999

Link zum Volltext

Verfügbarkeit prüfen

Unexpected Selectivities in C−H Activations of Toluene and p-Xylene at Cationic Platinum(II) Diimine Complexes. New Mechanistic Insight into Product-Determining Factors

Journal of the American Chemical Society, 2001-07, Vol.123 (27), p.6579-6590

2001

Link zum Volltext

Verfügbarkeit prüfen

Redox Chemistry of Dimethylplatinum(II) Diimine Complexes. Oxidatively Induced Pt−Me Transfer between Transient Platinum(III) Cation Radicals

Organometallics, 1998-08, Vol.17 (18), p.3957-3966

1998

Link zum Volltext

Verfügbarkeit prüfen

Oxidation of the ruthenium hydride complex (.eta.5-C5H5)Ru(CO)(PPh3)H: generation of a dihydrogen complex by oxidatively induced intermolecular proton transfer

Organometallics, 1991-01, Vol.10 (1), p.298-304

1991

Link zum Volltext

Verfügbarkeit prüfen

C−H Activation at a Cationic Platinum (II) Center: A Quantum Chemical Investigation

The journal of physical chemistry. A, Molecules, spectroscopy, kinetics, environment, & general theory, 1999-12, Vol.103 (48), p.10004-10008

1999

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3726: Preclinical activity of PSMA-TTC (BAY 2315497) in combination with androgen receptor antagonists in prostate cancer models

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3726-3726

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1141: Preclinical analysis of biodistribution and PET imaging of a zirconium-89 labeled PSMA-targeted antibody-chelator conjugate

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.1141-1141

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract 844: Preclinical activity of PSMA-TTC, a targeted alpha therapeutic in patient-derived prostate cancer models

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.844-844

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract 849: Synergistic effect of MSLN-TTC in combination with DNA damage response inhibitors

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.849-849

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract 855: Increased in vitro potency and in vivo efficacy of FGFR2-targeted thorium-227 conjugate (FGFR2-TTC) in combination with the ATR inhibitor BAY 1895344

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.855-855

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract 5200: Preclinical pharmacology of the PSMA-targeted thorium-227 conjugate PSMA-TTC: a novel targeted alpha therapeutic for the treatment of prostate cancer

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.5200-5200

2017

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers

Efficacy of a HER2-Targeted Thorium-227 Conjugate in a HER2-Positive Breast Cancer Bone Metastasis Model

Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer

In Vitro and In Vivo Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia

Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy

Solution Thermodynamics and Kinetics of Metal Complexation with a Hydroxypyridinone Chelator Designed for Thorium-227 Targeted Alpha Therapy

A Combined Experimental and Density Functional Theory Investigation of Hydrocarbon Activation at a Cationic Platinum(II) Diimine Aqua Complex under Mild Conditions in a Hydroxylic Solvent

An efficient chelator for complexation of thorium-227

Preclinical Combination Studies of an FGFR2 Targeted Thorium-227 Conjugate and the ATR Inhibitor BAY 1895344

Development of separation technology for the removal of radium-223 from targeted thorium conjugate formulations. Part II: purification of targeted thorium conjugates on cation exchange columns

Development of separation technology for the removal of radium-223 from targeted thorium conjugate formulations. Part I: purification of decayed thorium-227 on cation exchange columns

Development of separation technology for the removal of radium-223 from decayed thorium-227 in drug formulations. Material screening and method development

Synergistic Effect of a Mesothelin-Targeted 227Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models

Synergistic Effect of a Mesothelin-Targeted 227 Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models

Hydrocarbon Activation at a Cationic Platinum(II) Diimine Aqua Complex under Mild Conditions in a Hydroxylic Solvent

Unexpected Selectivities in C−H Activations of Toluene and p-Xylene at Cationic Platinum(II) Diimine Complexes. New Mechanistic Insight into Product-Determining Factors

Redox Chemistry of Dimethylplatinum(II) Diimine Complexes. Oxidatively Induced Pt−Me Transfer between Transient Platinum(III) Cation Radicals

Oxidation of the ruthenium hydride complex (.eta.5-C5H5)Ru(CO)(PPh3)H: generation of a dihydrogen complex by oxidatively induced intermolecular proton transfer

C−H Activation at a Cationic Platinum (II) Center: A Quantum Chemical Investigation

Abstract 3726: Preclinical activity of PSMA-TTC (BAY 2315497) in combination with androgen receptor antagonists in prostate cancer models

Abstract 1141: Preclinical analysis of biodistribution and PET imaging of a zirconium-89 labeled PSMA-targeted antibody-chelator conjugate

Abstract 844: Preclinical activity of PSMA-TTC, a targeted alpha therapeutic in patient-derived prostate cancer models

Abstract 849: Synergistic effect of MSLN-TTC in combination with DNA damage response inhibitors

Abstract 855: Increased in vitro potency and in vivo efficacy of FGFR2-targeted thorium-227 conjugate (FGFR2-TTC) in combination with the ATR inhibitor BAY 1895344

Abstract 5200: Preclinical pharmacology of the PSMA-targeted thorium-227 conjugate PSMA-TTC: a novel targeted alpha therapeutic for the treatment of prostate cancer

Suchergebnisse filtern